Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Blinded independent central review versus local investigator assessment of PFS in RCTs of immunotherapy in advanced cancers: A systematic review and meta-analysis.
D'Ambrosio S, Salomone F, Vitale F, Avanzo A, Viggiano A, Liguori L, Ferrara R, Nuccio A, Viscardi G, Napolitano F, Santaniello A, Formisano L, Bianco R, Servetto A. D'Ambrosio S, et al. Among authors: viscardi g. Eur J Cancer. 2024 Dec;213:115077. doi: 10.1016/j.ejca.2024.115077. Epub 2024 Oct 20. Eur J Cancer. 2024. PMID: 39454538 Free article.
Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies.
Nuccio A, Viscardi G, Salomone F, Servetto A, Venanzi FM, Riva ST, Oresti S, Ogliari FR, Viganò M, Bulotta A, Cameron R, Esposito A, Hines J, Bianco R, Reni M, Cascone T, Garassino MC, Torri V, Veronesi G, Cinquini M, Ferrara R. Nuccio A, et al. Among authors: viscardi g. Eur J Cancer. 2023 Dec;195:113404. doi: 10.1016/j.ejca.2023.113404. Epub 2023 Oct 26. Eur J Cancer. 2023. PMID: 37948842
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis.
Viscardi G, Tralongo AC, Massari F, Lambertini M, Mollica V, Rizzo A, Comito F, Di Liello R, Alfieri S, Imbimbo M, Della Corte CM, Morgillo F, Simeon V, Lo Russo G, Proto C, Prelaj A, De Toma A, Galli G, Signorelli D, Ciardiello F, Remon J, Chaput N, Besse B, de Braud F, Garassino MC, Torri V, Cinquini M, Ferrara R. Viscardi G, et al. Eur J Cancer. 2022 Dec;177:175-185. doi: 10.1016/j.ejca.2022.09.031. Epub 2022 Oct 5. Eur J Cancer. 2022. PMID: 36368251 Review.
Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC.
Hines JB, Cameron RB, Esposito A, Kim L, Porcu L, Nuccio A, Viscardi G, Ferrara R, Veronesi G, Forde PM, Taube J, Vokes E, Bestvina CM, Dolezal JM, Sacco M, Monteforte M, Cascone T, Garassino MC, Torri V. Hines JB, et al. Among authors: viscardi g. J Thorac Oncol. 2024 Jul;19(7):1108-1116. doi: 10.1016/j.jtho.2024.03.010. Epub 2024 Mar 8. J Thorac Oncol. 2024. PMID: 38461929 Free article.
Improved Event-Free Survival After Complete or Major Pathologic Response in Patients With Resectable NSCLC Treated With Neoadjuvant Chemoimmunotherapy Regardless of Adjuvant Treatment: A Systematic Review and Individual Patient Data Meta-Analysis.
Marinelli D, Nuccio A, Di Federico A, Ambrosi F, Bertoglio P, Faccioli E, Ferrara R, Ferro A, Giusti R, Guerrera F, Mammana M, Pittaro A, Sepulcri M, Viscardi G, Gallina FT. Marinelli D, et al. Among authors: viscardi g. J Thorac Oncol. 2024 Oct 9:S1556-0864(24)02374-8. doi: 10.1016/j.jtho.2024.09.1443. Online ahead of print. J Thorac Oncol. 2024. PMID: 39389220
Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program.
Prelaj A, Bottiglieri A, Proto C, Lo Russo G, Signorelli D, Ferrara R, Galli G, De Toma A, Viscardi G, Brambilla M, Lobefaro R, Nichetti F, Manglaviti S, Occhipinti M, Labianca A, Ganzinelli M, Gallucci R, Zilembo N, Greco GF, Torri V, de Braud F, Garassino MC. Prelaj A, et al. Among authors: viscardi g. Eur J Cancer. 2021 May;149:235-248. doi: 10.1016/j.ejca.2021.02.038. Epub 2021 Apr 2. Eur J Cancer. 2021. PMID: 33820681
Moving Immune Checkpoint Inhibitors to Early Non-Small Cell Lung Cancer: A Narrative Review.
Viscardi G, Vitiello F, Servetto A, Gristina V, Pizzutilo EG, Canciello MA, Medusa PM, Salomone F, Di Guida G, Mollica M, Aronne L, Scaramuzzi R, Napolitano F, Battiloro C, Caputo F, Gilli M, Totaro G, Curcio C, Rocco D, Montesarchio V. Viscardi G, et al. Cancers (Basel). 2022 Nov 25;14(23):5810. doi: 10.3390/cancers14235810. Cancers (Basel). 2022. PMID: 36497292 Free PMC article. Review.
Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers.
Lobefaro R, Viscardi G, Di Liello R, Massa G, Iacovino ML, Sparano F, Della Corte CM, Ferrara R, Signorelli D, Proto C, Prelaj A, Galli G, De Toma A, Brambilla M, Ganzinelli M, Trevisan B, Ciardiello F, De Braud F, Morgillo F, Garassino MC, Lo Russo G. Lobefaro R, et al. Among authors: viscardi g. Lung Cancer. 2021 Feb;152:165-173. doi: 10.1016/j.lungcan.2020.12.027. Epub 2020 Dec 28. Lung Cancer. 2021. PMID: 33421923
101 results